Biotech Daily Home

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here



Latest News !

Ausbiotech, Biotech Daily: 'Don't Cut the 45% R&D Tax Incentive'
- Sep 13, 2016

Pro Medicus: The Roll-Out Has Just Begun - Aug 22, 2016 

Protagonist Raises $117m, Lists on Nasdaq For Peptide Drugs

10-Year BDI-40 Up 163%, ASX200 Up 3%, Big Caps Up 308%

Teva Returns Mesoblast Heart Drug; Equity Facility - Jun 14, 2016

Biotech Daily Policy On Mega-Day-Traders - May 3, 2016

2015 - The Year In Review

Novartis Buys Spinifex For $916m

Genetic Technologies Dr Mervyn Jacobson 12 Months Gaol

Gaol For The Phosphagenics Three: Dr Esra Ogru
Dr Robert Gianello, Dr Woei-Jia Jiang

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization


September BDI-40 Up 2%, ASX200 Up 0.1%
Big Caps Down 1%, NBI Up 3%

Bionomics Up 92%, Osprey 42%, Benitec Down 26%, Actinogen 22%


October 3, 2016
The Biotech Daily Top 40 Index (BDI-40) continued to out-perform the ASX200, up 2.0 percent in September to a collective market capitalization of $8,446 million.
The S&P ASX200 edged up just 0.1 percent in September, while the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) fell a collective 1.25 percent, with Resmed retreating 6.0 percent to $11,858 million, CSL slipping 0.3 percent to $49,188 million and Cochlear up 0.5 percent to $8,114 million.
For the year to September 30, 2016, the BDI-40 was up 32.4 percent, the ASX200 rose 8.2 percent, with the Big Caps up a collective 22.5 percent (see chart below).
In the month of September, 21 of the BDI-40 companies were up, 11 by more than 10 percent, 17 were down, eight by more than 10 percent, with two companies unchanged.
Bionomics was the best, up 92.2 percent to $221 million on BNC210 trial data, followed by Osprey recovering 42.0 percent to $98 million, Opthea (37.5%), Dimerix (31.25%), Orthocell (27.3%), Airxpanders (18.75%), Neuren (15.8%) and Clinuvel (15.5%).
Benitec led the falls, down 26.3 percent to $14 million, followed by Actinogen (21.9%), Psivida (20.6%), Uscom (18.2%), Mesoblast (17.0%) and Anteo (16.2%).
Outside the BDI-40, eight companies have made significant gains in the month and year to September 30: Cynata was up 74.1 percent for the month and 51.5 percent for the year; followed by Phosphagenics (66.7%, 122.2%); Resapp (35.7%, 1,706.25%); Innate Immmunotherapeutics (32.1%, 270%); Paradigm (31.8%, 150.0%); Cogstate (29.1%, 320.8%); Dorsavi (21.7%, 170.4%); and Mayne Pharma (10.3%, 269.7%).
The Nasdaq Biotech Index rose 3.0 percent in September (down 4.5 percent for the year to September 30), with Aviragen (Biota) up 27.9 percent to $97 million, Sunshine Heart falling 31.8 percent to just $15 million, having dumped its C-Pulse heart pump technology and Israel’s Redhill, developing Giaconda’s assets, down 8.7 percent to $231 million. 
With Heartware’s acquisition by Medtronic and Sunshine Heart no longer developing its New Zealand-originated technology, Biotech Daily has ceased its coverage of both companies.
BDI-40 v S&P ASX200 Jun 30, 2006 to Sep 30, 2016 
BDI-40 v S&P ASX200 Sep 30, 2015 to Sep 30, 2016 
Big Caps (Cochlear, CSL, Resmed) Sep 30, 2015 to Sep 30, 2016


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At September 30, 2016



* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
   Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: